Phase I Dose Escalation Study Evaluating the Safety and Tolerability of PankoMab-GEX in Patients With Advanced, TA-MUC1 Positive Solid Malignancies Who Are Not Longer Eligible for Standard Therapy.
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2016
At a glance
- Drugs Anti-TA-MUC1 monoclonal antibody (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- 07 Jun 2016 Results published in the European Journal of Cancer
- 16 Oct 2013 Results published in Glycotope media release, and reported at this year's European Cancer Congress (ECCO 17), according to the media release.
- 01 May 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History